Core Insights - Zai Ding Pharma (ZLAB) opened with a 2.3% increase on August 13, reaching $35.1 per share, with a total market capitalization of $3.923 billion [1][2] Financial Performance - As of June 30, 2025, Zai Ding Pharma reported total revenue of $216 million, reflecting a year-on-year growth of 15.35% [1] - The company's net profit attributable to shareholders was -$89.165 million, showing a year-on-year increase of 33.33% [1][2] - Basic earnings per share for the fiscal year 2025 were reported at -$0.08 [2] Company Overview - Zai Ding Pharma is a patient-centered, innovative global biopharmaceutical company that is in the commercialization stage, focusing on providing optimal and first-in-class drugs for oncology, autoimmune diseases, infectious diseases, and central nervous system disorders [2] - The company's mission is to become a leading global biopharmaceutical company, offering transformative innovative drugs to patients in China and worldwide [2] - Zai Ding Pharma aims to establish itself as a global leader in biopharmaceuticals, with a foundation in China to provide innovative therapies for patients globally [2]